REPL Replimune

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" From Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have received an average recommendation of "Buy" from the seven analysts that are covering the firm, MarketBeat.com reports. Six equities r

10-04 02:12 ET

SVB Securities Adjusts Replimune Group's Price Target to $30 From $37, Reiterates Outperform Rating

09:09 AM EDT, 10/03/2022 (MT Newswires) -- Replimune Group (REPL) has an average rating of outperform and price targets ranging from $30 to $60, according to analysts polled by Capital IQ. (MT Newswir

10-03 09:10 ET

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Replimune Group (REPL) and Intercept Pharma (ICPT)

10-03 08:45 ET

Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday

Goldman Sachs raised Wells Fargo & Company (NYSE:WFC) price target from $46 to $48. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. Wells Fargo shares rose 1.1% to

10-03 07:16 ET

Replimune Group Is Maintained at Outperform by SVB Leerink

10-03 06:32 ET · Latest

Replimune Group Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 10/03/2022 73.71% SVB Leerink $37 → $30 Maintains Outperform 08/16/2022 148.99% Piper Sandler $44 → $43 Ma

10-03 06:22 ET

SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $30

SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and lowers the price target from $37 to $30.

10-03 06:22 ET

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne

09-29 06:35 ET

Analysts Conflicted on These Healthcare Names: Replimune Group (REPL), Minerva Surgical (UTRS) and Nektar Therapeutics (NKTR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Replimune Group (REPL – Research Report), Minerva Surgical (UTRS – Research Report) and Nektar Therapeutics (NKTR – Re

08-29 08:35 ET

Piper Sandler Trims Replimune Group (NASDAQ:REPL) Target Price to $43.00

Replimune Group (NASDAQ:REPL – Get Rating) had its target price reduced by Piper Sandler to $43.00 in a report released on Monday, Stock Target Advisor reports. REPL has been the subject of a number

08-26 02:41 ET